{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T03:23:02Z","timestamp":1790133782313,"version":"4.0.1"},"reference-count":60,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,28]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Positron emission tomography\u2013computed tomography (PET-CT) is recommended for response evaluation in aggressive large B-cell lymphoma (LBCL) but cannot detect minimal residual disease (MRD). Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for real-time disease monitoring. This study evaluated longitudinal ctDNA monitoring as an MRD marker in LBCL. In this prospective, single-center study, 14 newly diagnosed patients with LBCL receiving first-line immunochemotherapy underwent frequent longitudinal blood sampling. A 53-gene targeted sequencing panel quantified ctDNA and evaluated its kinetics, correlating it with clinical parameters and PET-CT, including total metabolic tumor volume (TMTV) calculated using artificial intelligence\u2013based analysis via RECOMIA. Baseline ctDNA was detected in 11 of 14 patients (79%) with a median variant allele frequency of 6.88% (interquartile range, 1.19%-10.20%). ctDNA levels correlated significantly with TMTV (\u03c1 = 0.90; P &amp;lt; .0001) and lactate dehydrogenase. ctDNA kinetics, including after 1 treatment cycle, mirrored PET-CT metabolic changes and identified relapsing or refractory patients. This study demonstrates ctDNA-based MRD monitoring in LBCL using a fixed targeted assay with an analytical sensitivity of at least 10\u22123. The kinetics of ctDNA reflects the clinical course and PET-CT findings, underscoring its complementary potential to PET-CT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016752","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T19:59:47Z","timestamp":1754337587000},"page":"5207-5218","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Monitoring ctDNA in aggressive B-cell lymphoma: a prospective correlative study of ctDNA kinetics and PET-CT metrics"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5507-9762","authenticated-orcid":false,"given":"Gayaththri","family":"Vimalathas","sequence":"first","affiliation":[{"name":"1Department of Clinical Research, University of Southern Denmark, Odense, Denmark"},{"name":"2Haematology-Pathology Research Laboratory, Research Unit for Haematology and Research Unit for Pathology, University of Southern Denmark and Odense University Hospital, Odense, Denmark"},{"name":"3Department of Pathology, Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3083-4850","authenticated-orcid":false,"given":"Marcus H\u00f8y","family":"Hansen","sequence":"additional","affiliation":[{"name":"1Department of Clinical Research, University of Southern Denmark, Odense, Denmark"},{"name":"2Haematology-Pathology Research Laboratory, Research Unit for Haematology and Research Unit for Pathology, University of Southern Denmark and Odense University Hospital, Odense, Denmark"},{"name":"4Department of Haematology, Odense University Hospital, Odense, Denmark"},{"name":"5Centre for Cellular Immunotherapy of Haematological Cancer Odense, Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6632-8039","authenticated-orcid":false,"given":"Oriane","family":"C\u00e9dile","sequence":"additional","affiliation":[{"name":"2Haematology-Pathology Research Laboratory, Research Unit for Haematology and Research Unit for Pathology, University of Southern Denmark and Odense University Hospital, Odense, Denmark"},{"name":"4Department of Haematology, Odense University Hospital, Odense, Denmark"},{"name":"5Centre for Cellular Immunotherapy of Haematological Cancer Odense, Odense University Hospital, Odense, Denmark"},{"name":"6Open Patient Data Explorative Network, Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0078-1217","authenticated-orcid":false,"given":"Mads","family":"Thomassen","sequence":"additional","affiliation":[{"name":"1Department of Clinical Research, University of Southern Denmark, Odense, Denmark"},{"name":"7Department of Clinical Genetics, Odense University Hospital, Odense, Denmark"},{"name":"8Clinical Genome Center, Department of Clinical Research, University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2041-3630","authenticated-orcid":false,"given":"Michael Boe","family":"M\u00f8ller","sequence":"additional","affiliation":[{"name":"1Department of Clinical Research, University of Southern Denmark, Odense, Denmark"},{"name":"2Haematology-Pathology Research Laboratory, Research Unit for Haematology and Research Unit for Pathology, University of Southern Denmark and Odense University Hospital, Odense, Denmark"},{"name":"3Department of Pathology, Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6427-4276","authenticated-orcid":false,"given":"Sara Kamuk","family":"Dahlmann","sequence":"additional","affiliation":[{"name":"2Haematology-Pathology Research Laboratory, Research Unit for Haematology and Research Unit for Pathology, University of Southern Denmark and Odense University Hospital, Odense, Denmark"},{"name":"4Department of Haematology, Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Louise Grube","family":"Kjeldsen","sequence":"additional","affiliation":[{"name":"2Haematology-Pathology Research Laboratory, Research Unit for Haematology and Research Unit for Pathology, University of Southern Denmark and Odense University Hospital, Odense, Denmark"},{"name":"4Department of Haematology, Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2720-9018","authenticated-orcid":false,"given":"Malene Grubbe","family":"Hildebrandt","sequence":"additional","affiliation":[{"name":"1Department of Clinical Research, University of Southern Denmark, Odense, Denmark"},{"name":"9Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6130-9736","authenticated-orcid":false,"given":"Anne Lerberg","family":"Nielsen","sequence":"additional","affiliation":[{"name":"1Department of Clinical Research, University of Southern Denmark, Odense, Denmark"},{"name":"9Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6761-8126","authenticated-orcid":false,"given":"Mohammad","family":"Naghavi-Behzad","sequence":"additional","affiliation":[{"name":"1Department of Clinical Research, University of Southern Denmark, Odense, Denmark"},{"name":"9Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0263-8820","authenticated-orcid":false,"given":"Lars","family":"Edenbrandt","sequence":"additional","affiliation":[{"name":"10Department of Molecular Medicine, University of Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0411-7594","authenticated-orcid":false,"given":"Charlotte Guldborg","family":"Nyvold","sequence":"additional","affiliation":[{"name":"1Department of Clinical Research, University of Southern Denmark, Odense, Denmark"},{"name":"2Haematology-Pathology Research Laboratory, Research Unit for Haematology and Research Unit for Pathology, University of Southern Denmark and Odense University Hospital, Odense, Denmark"},{"name":"4Department of Haematology, Odense University Hospital, Odense, Denmark"},{"name":"5Centre for Cellular Immunotherapy of Haematological Cancer Odense, Odense University Hospital, Odense, Denmark"},{"name":"6Open Patient Data Explorative Network, Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8418-6708","authenticated-orcid":false,"given":"Thomas Stauffer","family":"Larsen","sequence":"additional","affiliation":[{"name":"1Department of Clinical Research, University of Southern Denmark, Odense, Denmark"},{"name":"2Haematology-Pathology Research Laboratory, Research Unit for Haematology and Research Unit for Pathology, University of Southern Denmark and Odense University Hospital, Odense, Denmark"},{"name":"4Department of Haematology, Odense University Hospital, Odense, Denmark"},{"name":"5Centre for Cellular Immunotherapy of Haematological Cancer Odense, Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"issue":"12","key":"2025102810214824800_bib1","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2025102810214824800_bib2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"4","key":"2025102810214824800_bib3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated Diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"key":"2025102810214824800_bib4","doi-asserted-by":"crossref","first-page":"102443","DOI":"10.1016\/j.ctrv.2022.102443","article-title":"Treatment strategies for patients with diffuse large B-cell lymphoma","volume":"110","author":"Poletto","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"2025102810214824800_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"10254","key":"2025102810214824800_bib6","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"2025102810214824800_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"7","key":"2025102810214824800_bib8","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"10343","key":"2025102810214824800_bib9","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"4","key":"2025102810214824800_bib10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41408-021-00456-w","article-title":"Diffuse large B-cell lymphoma: new targets and novel therapies","volume":"11","author":"Cheson","year":"2021","journal-title":"Blood Cancer J"},{"issue":"9","key":"2025102810214824800_bib11","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"2025102810214824800_bib12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41408-023-00930-7","article-title":"Prognostic indices in diffuse large B-cell lymphoma: a population-based comparison and validation study of multiple models","volume":"13","author":"Jelicic","year":"2023","journal-title":"Blood Cancer J"},{"issue":"27","key":"2025102810214824800_bib13","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025102810214824800_bib14","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1182\/blood-2016-08-685073","article-title":"Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma","volume":"129","author":"Cohen","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2025102810214824800_bib15","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1053\/j.semnuclmed.2022.11.001","article-title":"PET\/CT in non-Hodgkin lymphoma: an update","volume":"53","author":"Zanoni","year":"2023","journal-title":"Semin Nucl Med"},{"issue":"34","key":"2025102810214824800_bib16","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1200\/JCO.2015.62.0229","article-title":"Routine imaging for diffuse large B-cell lymphoma in first complete remission does not improve post-treatment survival: a Danish-Swedish population-based study","volume":"33","author":"El-Galaly","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025102810214824800_bib17","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/ajh.23688","article-title":"Role of routine imaging in detecting recurrent lymphoma: a review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma","volume":"89","author":"El-Galaly","year":"2014","journal-title":"Am J Hematol"},{"issue":"13","key":"2025102810214824800_bib18","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1200\/JCO.2014.58.5729","article-title":"Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission","volume":"33","author":"Huntington","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025102810214824800_bib19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bjh.13420","article-title":"Prognostic value of complete remission status at end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis","volume":"170","author":"Adams","year":"2015","journal-title":"Br J Haematol"},{"issue":"11","key":"2025102810214824800_bib20","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s00259-014-2822-7","article-title":"Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma","volume":"41","author":"Sasanelli","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"30","key":"2025102810214824800_bib21","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in high-tumor burden follicular lymphoma: a pooled analysis of three multicenter studies","volume":"34","author":"Meignan","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"2025102810214824800_bib22","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/bloodadvances.2017015164","article-title":"Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma","volume":"2","author":"Delfau-Larue","year":"2018","journal-title":"Blood Adv"},{"issue":"4","key":"2025102810214824800_bib23","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2025102810214824800_bib24","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/bjh.17251","article-title":"Circulating tumour DNA in B-cell lymphomas: current state and future prospects","volume":"193","author":"Lakhotia","year":"2021","journal-title":"Br J Haematol"},{"issue":"34","key":"2025102810214824800_bib25","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1200\/JCO.2017.74.5281","article-title":"Minimal residual disease assessment in lymphoma: methods and applications","volume":"35","author":"Herrera","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025102810214824800_bib26","first-page":"1659","article-title":"DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells","volume":"61","author":"Jahr","year":"2001","journal-title":"Cancer Res"},{"issue":"2","key":"2025102810214824800_bib27","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.leu.2402016","article-title":"Tumor-related alterations in circulating DNA, potential for diagnosis, prognosis and detection of minimal residual disease","volume":"15","author":"Anker","year":"2001","journal-title":"Leukemia"},{"issue":"6","key":"2025102810214824800_bib28","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/14737159.2017.1319765","article-title":"The value of liquid biopsy in diagnosis and monitoring of diffuse large b-cell lymphoma: recent developments and future potential","volume":"17","author":"Camus","year":"2017","journal-title":"Expert Rev Mol Diagn"},{"issue":"3","key":"2025102810214824800_bib29","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40291-019-00390-5","article-title":"Detection of solid tumor molecular residual disease (MRD) using circulating tumor DNA (ctDNA)","volume":"23","author":"Chin","year":"2019","journal-title":"Mol Diagn Ther"},{"issue":"5","key":"2025102810214824800_bib30","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol"},{"issue":"28","key":"2025102810214824800_bib31","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"24","key":"2025102810214824800_bib32","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing","volume":"125","author":"Kurtz","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2025102810214824800_bib33","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-018-0111-6","article-title":"Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort","volume":"8","author":"Bohers","year":"2018","journal-title":"Blood Cancer J"},{"issue":"14","key":"2025102810214824800_bib34","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1182\/blood-2016-05-719641","article-title":"Diffuse large B-cell lymphoma genotyping on the liquid biopsy","volume":"129","author":"Rossi","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2025102810214824800_bib35","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1158\/1078-0432.CCR-20-2558","article-title":"Mutational landscape and tumor burden assessed by cell-free DNA in diffuse large B-cell lymphoma in a population-based study","volume":"27","author":"Rivas-Delgado","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2025102810214824800_bib36","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1182\/blood.2021012852","article-title":"Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma","volume":"139","author":"Meriranta","year":"2022","journal-title":"Blood"},{"issue":"23","key":"2025102810214824800_bib37","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1200\/JCO.20.02573","article-title":"Short diagnosis-to-treatment interval is associated with higher circulating tumor DNA levels in diffuse large B-cell lymphoma","volume":"39","author":"Alig","year":"2021","journal-title":"J Clin Oncol"},{"issue":"9","key":"2025102810214824800_bib38","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.3109\/10428194.2016.1139703","article-title":"Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma","volume":"57","author":"Camus","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2025102810214824800_bib39","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"issue":"5","key":"2025102810214824800_bib40","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nbt.3520","article-title":"Integrated digital error suppression for improved detection of circulating tumor DNA","volume":"34","author":"Newman","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"12","key":"2025102810214824800_bib41","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"4","key":"2025102810214824800_bib42","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/ijlh.14454","article-title":"Liquid biopsy for enhanced specificity in identifying somatic mutations in aggressive non-Hodgkin large B-cell lymphoma: a comparative study of cell-free DNA and formalin-fixed paraffin-embedded tissue","volume":"47","author":"Vimalathas","year":"2025","journal-title":"Int J Lab Hematol"},{"issue":"5","key":"2025102810214824800_bib43","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/bioinformatics\/btp698","article-title":"Fast and accurate long-read alignment with Burrows-Wheeler transform","volume":"26","author":"Li","year":"2010","journal-title":"Bioinformatics"},{"issue":"16","key":"2025102810214824800_bib44","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The sequence alignment\/map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"issue":"9","key":"2025102810214824800_bib45","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1101\/gr.107524.110","article-title":"The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data","volume":"20","author":"McKenna","year":"2010","journal-title":"Genome Res"},{"issue":"3","key":"2025102810214824800_bib46","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nbt.2514","article-title":"Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples","volume":"31","author":"Cibulskis","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"2","key":"2025102810214824800_bib47","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4161\/fly.19695","article-title":"A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff","volume":"6","author":"Cingolani","year":"2012","journal-title":"Fly (Austin)"},{"key":"2025102810214824800_bib48","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fgene.2012.00035","article-title":"Using drosophila melanogaster as a model for genotoxic chemical mutational studies with a new program, SnpSift","volume":"3","author":"Cingolani","year":"2012","journal-title":"Front Genet"},{"issue":"7809","key":"2025102810214824800_bib49","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature"},{"issue":"D1","key":"2025102810214824800_bib50","doi-asserted-by":"crossref","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","article-title":"ClinVar: improving access to variant interpretations and supporting evidence","volume":"46","author":"Landrum","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"7571","key":"2025102810214824800_bib51","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A global reference for human genetic variation","volume":"526","author":"Auton","year":"2015","journal-title":"Nature"},{"issue":"D1","key":"2025102810214824800_bib52","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: the catalogue of somatic mutations in cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"2025102810214824800_bib53","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2025102810214824800_bib54","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40658-020-00316-9","article-title":"RECOMIA-a cloud-based platform for artificial intelligence research in nuclear medicine and radiology","volume":"7","author":"Tr\u00e4g\u00e5rdh","year":"2020","journal-title":"EJNMMI Phys"},{"issue":"3","key":"2025102810214824800_bib55","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/cpf.12868","article-title":"Metabolic tumour volume in Hodgkin lymphoma-A comparison between manual and AI-based analysis","volume":"44","author":"Sadik","year":"2024","journal-title":"Clin Physiol Funct Imaging"},{"issue":"suppl 1","key":"2025102810214824800_bib56","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1182\/blood-2022-158183","article-title":"Biomarker-driven treatment strategy in high-risk large B-cell lymphoma: final results of a Nordic phase 2 study","volume":"140","author":"Leppa","year":"2022","journal-title":"Blood"},{"key":"2025102810214824800_bib57","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.exphem.2023.01.002","article-title":"Reproducibility of low-level residual myeloma immunoglobulin detection using ultra-deep sequencing","volume":"119-120","author":"C\u00e9dile","year":"2023","journal-title":"Exp Hematol"},{"key":"2025102810214824800_bib58","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.exphem.2021.03.005","article-title":"Perspective: sensitive detection of residual lymphoproliferative disease by NGS and clonal rearrangements-how low can you go?","volume":"98","author":"Hansen","year":"2021","journal-title":"Exp Hematol"},{"issue":"364","key":"2025102810214824800_bib59","doi-asserted-by":"crossref","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci Transl Med"},{"key":"2025102810214824800_bib60","doi-asserted-by":"crossref","first-page":"104234","DOI":"10.1016\/j.jbi.2022.104234","article-title":"Comparative evaluation of the heterozygous variant standard deviation as a quality measure for next-generation sequencing","volume":"135","author":"H\u00f8y Hansen","year":"2022","journal-title":"J Biomed Inform"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/20\/5207\/2416859\/blooda_adv-2025-016752-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/20\/5207\/2416859\/blooda_adv-2025-016752-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:31:12Z","timestamp":1761661872000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/20\/5207\/546478\/Monitoring-ctDNA-in-aggressive-B-cell-lymphoma-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":60,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025,10,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016752","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,28]]},"published":{"date-parts":[[2025,10,16]]}}}